Novartis launches strategic review of listed entity in India

19 February 2024

Pharma giant Novartis (NOVN: VX) has announced a strategic review of its listed entity in India.

Novartis India Limited (BSE: 500672) is listed on Bombay Stock Exchange. The Swiss corporation owns a 70.68% shareholding in the company.

"Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years"The entity is separate from Novartis Healthcare Private Limited, the wholly-owned subsidiary of the group in India, which includes a corporate center in Hyderabad, the commercial arm of the corporation in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK